New clinical developments in combination therapy for metastatic melanoma: ASCO annual congress, June 2022

Close metadata

INTRODUCTION

In the morbidity patterns of skin tumors, melanoma accounts for a relatively smaller percentage but is associated with a very high risk of an adverse outcome. The mortality rate of patients during the year since the diagnosis of melanoma in the Russian Federation in 2019 was 9.5%. The development and implementation of effective methods for melanoma treatment continue.

OBJECTIVE

To review advanced clinical developments for the drug therapy of metastatic melanoma, presented at the annual ASCO congress in June 2022.

MATERIALS AND METHODS

We searched the PubMed/Medline, MEDtalks.nl and Google databases with keywords «melanoma», «metastatic», «clinical trials», «ASCO», «2022», etc. Data sources in Dutch and English were selected.

RESULTS

The world is actively discussing the results of the annual ASCO Congress in June 2022, including the results of the most advanced research in the field of metastatic melanoma therapy: 1) RELATIVITY-047; 2) Tricotel phase 2 study; 3) interim results of a randomized, controlled phase 2 study of efficacy and safety of the combination of toripalimab (anti-PD-1 antibodies) and axitinib versus toripalimab or axitinib monotherapy in treatment-naïve patients with unresectable or metastatic mucosal melanoma; 4) phase 2 trials of efficacy and safety of camrelizumab (anti-PD-1 IgG4 antibodies) in combination with apatinib (VEGFR-2 tyrosine kinase inhibitor) and temozolomide in the first-line therapy in patients with advanced acral melanoma.

DISCUSSION

The results of the reviewed clinical developments demonstrate promising effects and an acceptable drug safety profile of combination therapy for metastatic melanoma. New targeted agents with different molecular targets can dramatically improve the rates of relapse-free and overall survival of patients and reduce the severity of the effect of melanoma escaping from the drug response.

Keywords:

metastatic melanoma

ASCO

clinical studies

targeted therapy

Authors:

Zavyalov A.A.

Research Institute for Healthcare Organization and Medical Management of Moscow Health Department;
Head of the Cancer Center of the Russian State Research Center — Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency

ORCID: 0000-0003-1825-1871

Andreev D.A.

Research Institute for Healthcare Organization and Medical Management of Moscow Health Department

ORCID: 0000-0003-0745-9474

Received:

26.08.2022

Accepted:

27.03.2023

List of references:

Lomas A, Leonardi‐Bee J, Bath‐Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol [Internet]. 2012; 166(5):1069-1080. https://doi.org/10.1111/j.1365-2133.2012.10830.x
Perez M, Abisaad JA, Rojas KD, Marchetti MA, Jaimes N. Skin cancer: Primary, secondary, and tertiary prevention. Part I. J Am Acad Dermatol [Internet]. 2022;87(2):255-268. https://linkinghub.elsevier.com/retrieve/pii/S0190962222002651
Kaprin AD, Starinskiy VV, Shakhzadova AO, editors. Zlokachestvennyye novoobrazovaniya v Rossii v 2019 godu (zabolevayemost’ i smertnost’). M.: MNIOI im. P.A. Gertsena — filial FGBU «NMITS radiologii» Minzdrava Rossii; 2020. (In Russ.).
Potekaev NN, Titov KS, Markin AA, Kashurnikov AY. Epidemiology of skin melanoma in the Russian Federation and in the city of Moscow for 10 years (2008—2018). Russian Journal of Clinical Dermatology and Venereology = Klinichaskaya dermatologiya i venerologiya [Internet]. 2020;19(6):810. https://www.mediasphera.ru/issues/klinicheskaya-dermatologiya-i-venerologiya/2020/6/1199728492020061810
Kaprin AD, Starinskiy VV, Shakhzadova AO, editors. Sostoyaniye onkologicheskoy pomoshchi naseleniyu Rossii v 2019 godu. M.a: MNIOI im. P.A. Gertsena — filial FGBU «NMITS radiologii» Minzdrava Rossii; 2020. (In Russ.).
Stylidi IS, Gevorkyan TG, Shpak AG. Improvement of indicators of federal project «Fight against oncological diseases». Vestnik Roszdravnadzora. 2021;1:46-53. (In Russ.).
American Society of Clinical Oncology. ASCO Annual Meeting 2022 [Internet]. 2022 [cited 2022 Jun 14]. https://meetings.asco.org/meetings/2022-asco-annual-meeting/288/program-guide/scheduled-sessions
Risk en Business, van Stigt Thans J. Europese vergelijking: Meer kanker in Nederland dan in andere EU-landen. [Internet]. 2020 [cited 2022 Aug 11]. https://www.riskenbusiness.nl/nieuws/claims/europese-vergelijking-meer-kanker-in-nederland-dan-in-andere-eu-landen/
GBU «NIIOZMM DZM», Andreyev DA. Nauchnyy seminar: «Kontrol’ kachestva i bezopasnosti meditsinskoy deyatel’nosti po profilyu «Onkologiya». g. Moskva (on-layn). Doklad: «Analiz opyta otsenki kachestva meditsinskoy deyatel’nosti v onkologii na primere stran Zapadnoy Yevropy». [Internet]. 2020 [cited 2022 Aug 11]. (In Russ.) https://niioz.ru/news/zapis-i-itogi-vebinara-niiozmm-dzm-po-voprosam-kontrolya-kachestva-i-bezopasnosti-v-onkologicheskoy-/
European Commission. Cancer burden statistics and trends across Europe. [Internet]. 2020 [cited 2020 Oct 21]. https://ecis.jrc.ec.europa.eu/%0A
MEDtalks, Blank C, Suijkerbuijk K. When two experts meet Chicago 2022. Melanoom. Het belangrijkste nieuws van de ASCO 2022 op het gebied van melanoom. [Internet]. 2022 [cited 2022 Aug 15]. https://www.medtalks.nl/asco2022-melanoom
National Library of Medicine. A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma (RELATIVITY-047). [Internet]. 2022 [cited 2022 Aug 15]. https://clinicaltrials.gov/ct2/show/NCT03470922
National Library of Medicine. A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous [Internet]. 2022 [cited 2022 Aug 15]. https://clinicaltrials.gov/ct2/show/NCT03625141
National Library of Medicine. Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma (BJCH-MM-0624). [Internet]. 2022 [cited 2022 Aug 15]. https://www.clinicaltrials.gov/ct2/show/NCT03941795
National Library of Medicine. Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma. [Internet]. 2022 [cited 2022 Aug 15]. https://www.clinicaltrials.gov/ct2/show/NCT04397770
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Lao CD, et al. CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma. J Clin Oncol [Internet]. 2021;39(15 suppl):9506. https://doi.org/10.1200/JCO.2021.39.15_suppl.9506
Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med [Internet]. 2022;386(1):24-34. https://doi.org/10.1056/NEJMoa2109970
Durham NM, Nirschl CJ, Jackson CM, Elias J, Kochel CM, Anders RA, et al. Lymphocyte Activation Gene 3 (LAG-3) Modulates the Ability of CD4 T-cells to Be Suppressed In Vivo. Kassiotis G, editor. PLoS One [Internet]. 2014;9(11):e109080. https://doi.org/10.1371/journal.pone.0109080
Long G V, Hodi FS, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, et al. Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047). J Clin Oncol [Internet]. 2022; 40(36 suppl): 360385. https://doi.org/10.1200/JCO.2022.40.36_suppl.360385
Tawbi HA, Hodi FS, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, et al. Nivolumab (NIVO) + relatlimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma: OS and ORR by key subgroups from RELATIVITY-047. J Clin Oncol [Internet]. 2022;40 (16 suppl):9505. https://doi.org/10.1200/JCO.2022.40.16_suppl.9505
Dummer R, Queirolo P, Abajo Guijarro AM, Hu Y, Wang D, Azevedo SJ, et al. Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAFV600 mutation — positive melanoma with central nervous system (CNS) metastases (mets): Primary results from phase 2 Tricotel study. J Clin Oncol [Internet]. 2022;40(16 suppl):9515. https://doi.org/10.1200/JCO.2022.40.16_suppl.9515
Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet [Internet]. 2020;395(10240):1835-1844. https://linkinghub.elsevier.com/retrieve/pii/S014067362030934X
Cui C, Lian B, Sheng X, Xu H, Si L, Chi Z, et al. Toripalimab plus axitinib versus toripalimab or axitinib alone in patients with treatment-naive unresectable or metastatic mucosal melanoma: Interim results from a randomized, controlled, phase II trial. J Clin Oncol [Internet]. 2022;40(16 suppl):9512. https://doi.org/10.1200/JCO.2022.40.16_suppl.9512
National Library of Medicine. Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma (BJCH-MM-0624). [Internet]. 2022 [cited 2022 Aug 15]. https://clinicaltrials.gov/ct2/show/NCT03941795
Si L, Li C, Bai X, Zhou L, Mao L, Cui C, et al. A phase II clinical trial of camrelizumab (CAM, an IgG4 antibody against PD-1) combined with apatinib (APA, a VEGFR-2 tyrosine kinase inhibitor) and temozolomide (TMZ) as the first-line treatment for patients (pts) with advanced acral melanoma (AM). J Clin Oncol [Internet]. 2022;40(16 suppl):9508. https://doi.org/10.1200/JCO.2022.40.16_suppl.9508
National Library of Medicine. Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma. [Internet]. 2022 [cited 2022 Aug 15]. https://clinicaltrials.gov/ct2/show/NCT04397770
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J-J, Cowey CL, et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med [Internet]. 2017;377(14): 1345-1356. https://doi.org/10.1056/NEJMoa1709684
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Lao CD, et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol [Internet]. 2022;40(2):127-137. https://doi.org/10.1200/JCO.21.02229
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Melanoma: Cutaneous. Version 3.2022 — April 11, 2022. [Internet]. 2022 [cited 2022 Aug 16]. https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf
Seth R, Messersmith H, Kaur V, Kirkwood JM, Kudchadkar R, McQuade JL, et al. Systemic Therapy for Melanoma: ASCO Guideline. J Clin Oncol [Internet]. 2020;38(33):3947-3970. https://doi.org/10.1200/JCO.20.00198

Close metadata